The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization

Jing Zou, Xuping Xie, Camila Fontes-Garfias, Kena A. Swanson, Isis Kanevsky, Kristin Tompkins, Mark Cutler, David Cooper, Philip R. Dormitzer, Pei-Yong Shi

Research output: Contribution to journalArticlepeer-review


Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we report that the D614G mutation modestly reduced (1.7–2.4-fold) SARS-CoV-2 neutralization by BNT162b2 vaccine-elicited mouse, rhesus, and human sera, concurring with the 95% vaccine efficacy observed in clinical trial.

Original languageEnglish (US)
Article number44
Journalnpj Vaccines
Issue number1
StatePublished - Dec 2021

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization'. Together they form a unique fingerprint.

Cite this